MM-111

N/A

Report date: 2024/06/27 20:00:09

Base Information

Drug NameMM-111
Drug Alias NameMM-111
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonistsReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2Receptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerrimack Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerrimack Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[7] 

Other Information

ATC CodeN/A
Related LinksN/A